Tag Archives: Andreesen Horowitz
← Older postsScribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter
The first generation of CRISPR-based therapies showed how the technology can edit DNA, making genetic fixes to unwanted mutations. But those treatments use the CRISPR system as scientists found it in nature, which means it still has limitations when applied to humans, says Benjamin Oakes, CEO of Scribe Therapeutics. Scribe aims to develop gene-editing therapies […]
Posted in Boston blog main, Boston top stories, National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged Amyotrophic Lateral Sclerosis (ALS), Andreesen Horowitz, Ben Oakes, Biogen, Biotech, clinical trials, CRISPR, Editas Medicine, FDA, Innovative Genomics Institute, Jennifer Doudna, Leber Congenital Amaurosis type 10, Life Sciences, Scribe Therapeutics, startups, University of California at Berkeley | Comments Off on Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next ChapterBio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More
Perhaps the most talked-about news at the JP Morgan Healthcare Conference this week was a new startup that launched with $200 million and an ambitious claim that its first drug would be approved within five years, and 10 in total within as many years. Cambridge, MA-based EQRx contends it will be able achieve its goals […]
Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Adaptimmune, Adaptive Phage Therapeutics, Alexis Borisy, Aligos Therapeutics, Allogene Therapeutics, Amarin, amazon, Amunix Pharmaceuticals, Andelyn Biosciences, Andreesen Horowitz, Astellas, AstraZeneca, bayer, BioCryst, Biogen, BioNtech, Biotech, Charles Gayer, clinical trials, CRISPR, Dare Bioscience, deals, Department of Defense, Derek Lowe, Dermira, Disarm Therapeutics, Eli Lilly, Elliot Norry, Emendo Biotherapeutics, epilepsy, EQRx, FDA, Frazier Healthcare Partners, Gene Therapy, Generation Bio, Gilead Sciences, Human Longevity, I-Mab, Idorsia, Incyte, Insilico Medicine, IPO, Ipsen, IT, Jorge Conde, Kyverna Therapeutics, Life Sciences, Lymphoma, Machine Learning, MorphoSys, Nationwide Children’s Hospital, Nektar Therapeutics, NeoGenomics, Neon Therapeutics, Neurocrine Biosciences, opioid, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Schrödinger, Scott Holmes, Software, SpringWorks Therapeutics, startups, Steven Hildemann, Tyra Biosciences | Comments Off on Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & MoreBiotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More
The brain has stymied many efforts to develop new neuroscience drugs, leading a number of big pharmaceutical companies to pull back on such R&D work. This week, Amgen joined them. Amgen (NASDAQ: AMGN) is ending its research and early development programs in neuroscience, the company announced during a conference call to discuss third-quarter financial results. […]
Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Alkermes, Alphabet, AMAG Pharmaceuticals, Amgen, Andreesen Horowitz, Anne Traas, Assembly Bio, Astellas Pharma, AstraZeneca, Autoimmune Diseases, BeiGene, Bicycle Therapeutics, Biogen, Biotech, Bob Bradway, cancer, Cardiovascular Diseases, clinical trials, Context Therapeutics, Cystic Fibrosis, Cystic Fibrosis Foundation, David Eatwell, David Hung, Dicerna Pharamceuticals, diroximel fumarate, Ed Tucker, Editas Medicine, ER, erenumab, FDA, Fitbit, Genmab, Gilead Sciences, GlaxoSmithKline, google, Hepatitis B, hydroxyprogesterone caproate, I-Mab, Illumina, IMV, Inflammatory Disease, Ironwood Pharmaceuticals, José Octávio Costa Filho, Judith Abrams, Life Sciences, Matthew Sause, Medivation, Migraine, Mirati Therapeutics, Mirum Pharmaceuticals, Multiple Sclerosis, Neuroscience, Nigel Crockett, Nuvation Bio, Oncology, Oyster Point Pharmaceuticals, Pacific Biosciences, Pandion Therapeutics, Passage Bio, Pear Therapeutics, Pfizer, Rafael Pharmaceuticals, RAPT Therapeutics, Richard Morris, Roche, Roche Diagnostics, Scout Bio, Servier, Spark Therapeutics, Tecfidera, Thomas Russo, Tmunity Therapeutics, Type 1 diabetes, University of Pennsylvania, Wisconsin Venture Investors, Zolgensma | Comments Off on Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & MoreBio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More
The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers. First, […]
Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged Abiraterone, Allergan, Amgen, Amgen Helix campus, Amicus Therapeutics, Andreesen Horowitz, Arcturus Therapeutics, Biogen, Biotech, blockchain, bortezomib, Bristol-myers Squibb, cancer, Celgene, David Mitchell, deals, dexamethasone, Drugs, duvelisib, Enzalutamide, FDA, fremanezumab, George Church, Gilead Sciences, GlaxoSmithKline, Hans Bishop, Harvard University, HIV, Immunotherapy, Infinity Pharmaceuticals, Intarcia Therapeutics, Ipilimumab, Juno Therapeutics, Life Sciences, Lung Cancer, Migraines, Natalizumab, Nationa Institutes of Health, Nebula Genomics, Nektar Therapeutics, Nivolumab, Opdivo, Pomalidomide, Pomalyst, Pompe disease, Roundups, Sema4, startups, Stroke, Teva Pharmaceutical, Theravance biopharma, Tysabri, ubrogepant, VC, Velcade, Verastem, Xoc Pharmaceuticals, Yervoy | Comments Off on Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & MorePresence Capital Takes the Temperature of VR/AR at Mid-Year
This week we checked in with Presence Capital, a San Francisco-based venture capital firm that specializes in virtual reality and augmented reality startups. Presence, which made its first investment in July 2015, has now invested in 33 companies, including VR animation studio Baobab; Strivr, a creator of VR training systems; Meta, the developer of a […]
Posted in National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged AltspaceVR, Amitt Mahajan, Andreesen Horowitz, apple, Apple ARKit, Applied VR, Artificial Intelligence (AI), Augmented Reality, Baobab, Betaworks, deals, Devices, Entrepreneurship, facebook, Financing, funding, Glass Enterprise Edition, google, Google Glass, Hardware, Holograms, HTC Vive, Internet, Investor, IT, Linden Lab, Magic Leap, meta, Microsoft, Microsoft’s Hololens, Mobile, Oculus Rift, Playstation VR, Presence Capital, Rothenberg Ventures, Samsung GearVR, SanFranciscoVC, Sequoia Capital, Snapchat, Software, sony, startups, Strivr, SVAngel, VC, Venture Capital, Virtual Reality (VR), Voice Interactivity, WalMart, Web, Zynga | Comments Off on Presence Capital Takes the Temperature of VR/AR at Mid-YearSan Antonio’s Geekdom Fund Adds to Investments With $20M Second Fund
San Antonio—The Texas IT-focused venture capital firm Geekdom Fund has closed a $20 million fund, which it started raising last year. The San Antonio venture firm was founded in 2014 by Michael Girdley, Don Douglas, Mike Troy, and Cole Wollak, and closed its first fund at $3.4 million in 2015. Geekdom Fund has always invested […]
Posted in Boston blog main, National blog main, San Francisco blog main, Texas, Texas blog main, Texas top stories | Tagged acquire, acquired, Acquisition, Andreesen Horowitz, Athenahealth, Chowbiotics, cisco, Cole Wollak, Dauber, Don Douglas, Geekdom, Geekdom Fund, Geekdom Fund II, investing, investmetn, IT startups, Medspoke, Merge VR, Michael Girdley, Mike Troy, Patient IO, San Antonio, San Antonio VC, San Antonio venture capital, Sea Machines, SeatSmart, Tech, Technology, Tenfold, TexasVC, TicketIQ, VC, Venture Capital, WorkLife | Comments Off on San Antonio’s Geekdom Fund Adds to Investments With $20M Second FundSenate Confirms Price for HHS, But Stock Deals Still Raise Questions
The Senate confirmed Tom Price as Secretary of the U.S. Department of Health and Human Services early Friday morning by a 52-47 vote that, as expected, fell largely on party lines. Price is an orthopedic surgeon by training who has been a member of Georgia’s congressional delegation since 2004. He will now oversee a department that […]
Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged Andreesen Horowitz, Balaji Srinivasan, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Department of Health and Human Services, Donald Trump, Fairleigh Dickinson University, FDA, Food and Drug Administration, Innate Immunotherapeutics, Life Sciences, National Institutes of Health, New Enterprise Associates, Peter Thiel, Tom Price, Zimmer Biomet | Comments Off on Senate Confirms Price for HHS, But Stock Deals Still Raise QuestionsStart Houston, Gigster Partner to Match Developers With Startups
Start Houston co-founder and tech entrepreneur Apurva Sanghavi found himself in a predicament familiar to many entrepreneurs: an incomplete project was stalled because of a lack of developers. Almost on a whim, he turned to Gigster, a San Francisco-based startup that connects freelance developers to entrepreneurs like Sanghavi. Hiring Gigster gave him the developer talent […]
Posted in National blog main, National top stories, San Francisco blog main, Texas, Texas blog main, Texas top stories | Tagged Accelerator, Andreesen Horowitz, Apurva Sanghavi, co-working, Curiosoft, Dallas, Demo Day, developers, Engineers, entrepreneurs, funding, Gaurav Khandelwal, Gigster, Houston, investment, IT, Mafia Wars, people, programmers, Roger Dickey, San Francisco, Software, Start Houston, startups, talent, Venture Capital, Workforce, Zynga | Comments Off on Start Houston, Gigster Partner to Match Developers With StartupsTechstars Alum DigitalOcean to Double Staff, Office Space with $83M
Next week, the team at DigitalOcean will move into a 30,000-square-foot office, in the same building but twice the size of its current digs, as it ramps up with more funding in hand. The New York-based company hosts cloud infrastructure, largely used by developers to build websites and apps. Along with the extra elbow room, […]
Posted in Boulder/Denver blog main, National blog main, New York, New York blog main, New York top stories | Tagged Access Industries, Andreesen Horowitz, Atlantic.Net, BlueMix, cloud computing, cloud hosting, Cloud-Based Services, deals, DigitalOcean, GitHub, IBM, IT, Mitch Wainer, oracle, startups, TechStars | Comments Off on Techstars Alum DigitalOcean to Double Staff, Office Space with $83MVC Funding Slows as Big Funds Crowd into Late-Stage Venture Deals
Following a December surge, when U.S. venture firms invested $7.2 billion in 342 deals nationwide, VC activity reset at a lower pace during the first quarter of 2015, according to data being released today by CB Insights. The New York venture capital tracker says VCs invested $11.3 billion in 805 startups over the three months […]
Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Accela, acquisitions, Algal Scientific, Allergen Research Corp., Andreesen Horowitz, Biotech, CB Insights, cleantech, Devices, Entrepreneurship, Financing, funding, healthcare, Hedge Funds, innovation, Innovation Economy, Internet, IPOs, IT, Life Sciences, Lyft, Lynda, M&As, Mergers & Acquisitions, Mobile, Mutual Funds, Pinterest, Private Equity Funds, Sakti3, Simplivity, Snapchat, Social Finance, Software, startups, Tech, Telecom, Uber, VC, Venture Capital, Venture Capital Surveys, wireless | Comments Off on VC Funding Slows as Big Funds Crowd into Late-Stage Venture Deals← Older postsArchives
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- July 2006
- June 2006
- April 2006
- March 2006
- February 2006
- January 2006
- December 2005
- October 2005
- September 2005
- August 2005
- July 2005
- June 2005
- May 2005
- April 2005
- March 2005
- February 2005
- January 2005
- December 2004
- September 2004
- June 2004
- May 2004
- March 2004
- February 2004
- January 2004
- December 2003
- June 2003
- May 2003
- March 9
Meta